Release Date: March 31, 2017
Expiration Date: March 31, 2018
Media: Internet - based
Community Practice Connections™: 1st Annual International Congress on Immunotherapies in Cancer™: Focus on Practice-Changing Application features case-based discussion of the application of immune checkpoint inhibitors in several tumor types. Interactive clinical vignettes are followed by short video interviews with leading oncology experts and short summaries of clinical data related to these clinical settings. The video interviews address decision points in the clinical vignettes, as well as questions commonly faced in the community oncology practice setting by physicians using immunotherapy.
CME/CE Activity Table of Contents
- Module 1. A Patient With Platinum-Pretreated Bladder
- Module 2: A Patient With Recurrent Head & Neck Cancer
- Module 3. Metastatic Lung Cancer (squamous and nonsquamous)
- Module 4. A Patient With Advanced, Previously Treated Melanoma
Instructions for This Activity and Receiving Credit
This educational activity is directed toward oncologists, nurses, and pharmacists. Participants will be primarily those whose practice requires mastery and a critical understanding of the fundamental principles, pivotal published studies, and emerging information on the immunotherapies, and their evolving roles in the treatment of cancer.
At the conclusion of this activity, you should be better prepared to:
- Explain current and evolving mechanistic approaches concerning how the immune system can be targeted in the treatment of cancer.
- Evaluate clinical trial findings on immuno-oncology strategies and how they can be practically applied to the management of cancer in multiple lines of care.
- Discuss emerging methods to personalize care via the use of biomarkers and other methods to individualize the use of immuno-oncology strategies.
- Describe how common and uncommon adverse events, associated with the use of immuno-oncology strategies, can be proactively mitigated and managed.
- Detail important remaining clinical questions in the field, and highly anticipated ongoing clinical trials, that are evaluating emerging immuno-oncology strategies.
Faculty, Staff, and Planners' Disclosures
Antoni Ribas, MD, PhD
Professor of Medicine
Professor of Surgery
Professor of Molecular & Medical Pharmacology
David Geffen School of Medicine
Director, Tumor Immunology Program, Jonsson Comprehensive Cancer Center
University of California, Los Angeles
Los Angeles, California, USA
Disclosure: Consultant: Merck, Novartis, Roche; Shareholder: Abraxis, CytomX, Compugen, Five Prime, Kite Pharma
Daniel P. Petrylak, MD
Professor of Medicine, Medical Oncology
Director, Prostate and GU Medical Oncology
Director, Prostate Cancer Translational Research Group
New Haven, CT
Disclosure: Grant/Research Support: Oncogenix, Progenics, Johnson and Johnson, Millineum, Celgene, Dendreon, Sanofi, Agenysis, Eli Lilly, Roche Laboratories; Consultant: Bayer, Bellicum, Dendreon, Sanofi Avenitis, Johnson and Johnson, Exelixis, Ferring, Millineum, Medivation, Pfizer, Roche Laboratories, Tyme pharmaceuticals; Shareholder: Bellicum, Tyme
Tanguy Seiwert, MD
The University of Chicago Medicine
Disclosure: Consultant: Amgen, Astra Zeneca, BMS, Celgene, Innate, Jounce, Lilly, Merck, Merck-Serono
Naiyer A Rizvi, MD
Director, Thoracic Oncology
Price Chair, Clinical Translational Research
Columbia University Medical Center
New York, NY
Disclosure: Consultant: Merck, Roche, BMS, AZ; Shareholder: Gritstone Oncology
Disclosure Policy and Resolution of Conflicts of Interest (COI)
As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME/CE activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME/CE activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.
Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This CME/CE activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME/CE activity is for continuing medical and nursing education purposes only, and is not meant to substitute for the independent clinical judgment of a physician relative to diagnostic or treatment options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER®.
CME/CE Provider Contact Information
Physicians’ Education Resource®, LLC
2 Clarke Drive
Cranbury, NJ 08512
Hardware And Software Requirements
Internet Explorer v.7 or greater (for Windows) | Mozilla Firefox v.2 or greater (for Windows, Mac, Linux)
Minimum System Requirements (Windows)
- A Pentium-based PC or compatible computer
- At least 64MB of RAM
- Windows 95/98/NT/ME/2000/XP/Vista system software
- Screen resolution of 1024 x 786 or larger recommended
- PDF Reader: Adobe Reader 5.0 or higher, Foxit Reader 2.0 or likewise
Minimum System Requirements (Mac OS)